ArticleThe Journal of experimental medicine2021
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.
Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Affinity- and epitope-dependent pathogenicity of GM-CSF autoantibodies in patients with autoimmune pulmonary alveolar proteinosis.Nature communications · 2026Article
- KLF2 expression in IgG plasma cells at their induction site regulates the migration program.The Journal of experimental medicine · 2025Article
- Evolution of Zika virus inVirus evolution · 2025Article
- Designing strong inducible synthetic promoters in yeasts.Nature communications · 2024Article
- Clonal landscape of autoantibody-secreting plasmablasts in COVID-19 patients.Life science alliance · 2024Article
- Reduced cross-protective potential of Omicron compared to ancestral SARS-CoV-2 spike vaccines against potentially zoonotic coronaviruses.Npj viruses · 2024Article
- Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses.PLoS pathogens · 2024Article
- Heterologous Sarbecovirus Receptor Binding Domains as Scaffolds for SARS-CoV-2 Receptor Binding Motif Presentation.ACS infectious diseases · 2024Article
- Memory B cells.Nature reviews. Immunology · 2024Review
- Heterologous sarbecovirus receptor binding domains as scaffolds for SARS-CoV-2 receptor binding motif presentation.bioRxiv : the preprint server for biology · 2023Article
- Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients.Nature communications · 2023Article
- Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees.The Journal of experimental medicine · 2023Article
- Glycosylation in SARS-CoV-2 variants: A path to infection and recovery.Biochemical pharmacology · 2022Review
- Cell-specific targeting of extracellular vesicles through engineering the glycocalyx.Journal of extracellular vesicles · 2022Article
- Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.Science (New York, N.Y.) · 2022Article
- Neutralizing Antibody Response toViruses · 2022Article
- Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice.Virology journal · 2022Article
- Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models.bioRxiv : the preprint server for biology · 2022Article
- Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting.Cell reports · 2022Article
- Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.Cell reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 2 countries.
Funding
Abstract
Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD-specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.